Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial

Chandrajit P. Raut, N. Joseph Espat, Robert G. Maki, Dejka M. Araujo, Jonathan Trent, Toni Faith Williams, D. Das Purkayastha, Ronald P. Dematteo

Research output: Contribution to journalArticlepeer-review

25 Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences